Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Arcutis Biotherapeutics (ARQT) Stock Price & Analysis
618 Followers
ARQT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $15.12
Previous Close$7.88
Volume804.91K
Average Volume (3M)3.90M
Market Cap
$897.05M
Enterprise Value$844.39M
Total Cash (Recent Filing)$271.86M
Total Debt (Recent Filing)$205.92M
Price to Earnings (P/E)-1.4
Beta0.93
Next Earnings
May 14, 2024EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.65
Shares Outstanding96,813,363
10 Day Avg. Volume2,245,188
30 Day Avg. Volume3,899,778
Standard Deviation0.28
R-Squared0.05
Alpha0.00661
Financial Highlights & Ratios
Price to Book (P/B)9.36
Price to Sales (P/S)12.80
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.17
Enterprise Value/Gross Profit15.46
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$16.40Price Target Upside111.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Arcutis Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Analyst Sentiment & Stock PotentialAnalyst maintains a Buy rating on ARQT, signaling confidence in the stock's potential for growth due to robust product performance and market potential.
Product Portfolio & Regulatory ApprovalsThe potential FDA approval for Zoryve Cream in atopic dermatitis could significantly expand the market and drive increased sales.
Product Sales & Market AdoptionZoryve sales exceeding expectations, coupled with improved reimbursement rates, indicate strong market adoption and potential for continued revenue growth.
Bears Say
Market PerformanceZoryve Foam experienced a significant sell-off due to weak growth, raising concerns about its performance stability.
Prescription TrendsZoryve Cream and other branded topicals like Opzelura and VTAMA saw a decline in total prescriptions, indicating a competitive setback.
Regulatory ChallengesComplex generics such as topicals have historically had difficulties obtaining FDA approval, and additional differences could add to the complexity.
---
Ownership Overview
23.00% Insiders
23.42% Mutual Funds
30.17% Other Institutional Investors
23.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $1.76 and its highest was $15.12 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Currently, no data Available
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is May 14, 2024 which is in 6 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Feb 27, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.782 by $0.062.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -$0.69.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 115,524,990 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.782. Following the earnings report the stock price went up 9.701%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Graham Capital Management, L.P.. It holds Arcutis Biotherapeutics’s shares valued at 202K.
---
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.40 (111.20% Upside)
$16.40 (111.20% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $159.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.02%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q4 2024
0:00 / 0:00
---
ARQT Stock 12 Month Forecast
Average Price Target
$16.40
▲(111.20% Upside)
Technical Analysis
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
+1.51%
reiterated a buy rating 2 months ago
Copying Vikram Purohit's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of +1.51% per trade.
---